1. In Vivo
  2. >>Archive

Total Ankle Replacement Sparks New Race

Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.

Orthopedic companies are being forced to search far and wide for markets with true growth potential. Established orthopedics companies Stryker Corp. and Smith & Nephew PLC have set up businesses in emerging market countries including China, India, and Brazil and in some cases have bolstered their presence through the acquisition of domestic companies. Even Medtronic PLC, which sells only spine devices in the US and Europe, jumped into China’s orthopedics industry with the acquisition of China Kanghui Holdings in 2012. [See Deal] (SeeAlso see "Could Medtronic’s Kanghui Purchase Set Course For US Entry?" - In Vivo, 22 October, 2012..)

But the search for growth isn’t limited to far off lands. Orthopedic companies like Stryker, Zimmer Biomet Holdings Inc.,...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.